Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

EU/LA Pearl Index Study - Transdermal Contraceptive Patch

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00914693
First received: May 5, 2009
Last updated: December 4, 2014
Last verified: December 2014
  Purpose
The aim of the present study is to prove efficacy and safety of a new contraceptive patch.

Condition Intervention Phase
Contraception
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Occurrence of pregnancy [ Time Frame: 13 treatment cycles each consisting of 28 days and follow-up period of 14 days ]

Secondary Outcome Measures:
  • Cervical smear [ Time Frame: 13 treatment cycles each consisting of 28 days ]
  • Adverse events [ Time Frame: 13 treatment cycles each consisting of 28 days ]
  • Bleeding pattern and cycle control [ Time Frame: 13 treatment cycles each consisting of 28 days ]

Other Outcome Measures:
  • Treatment compliance [ Time Frame: 13 treatment cycles each consisting of 28 days ]
  • Subjective assessment of satisfaction with the treatment [ Time Frame: 13 treatment cycles each consisting of 28 days ]

Enrollment: 1694
Study Start Date: April 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Ethinylestradiol/Gestodene (BAY86-5016)
7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Requiring contraception
  • Normal cervical smear
  • Smokers not older than 30 years
  • History of regular cyclic menstrual periods

Exclusion Criteria:

  • Pregnancy or lactation
  • Obesity (BMI> 30 kg/m2
  • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Use of other contraceptive methods than study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00914693

  Show 66 Study Locations
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00914693     History of Changes
Other Study ID Numbers: 91554
2008-004214-27 ( EudraCT Number )
310801 ( Other Identifier: Company internal )
Study First Received: May 5, 2009
Last Updated: December 4, 2014

Keywords provided by Bayer:
Fertility control
Contraception

Additional relevant MeSH terms:
Ethinyl Estradiol
Gestodene
Contraceptive Agents
Femovan
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Progestins

ClinicalTrials.gov processed this record on April 28, 2017